BridgeBio’s great week, Moderna’s fall

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween?

We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the company’s positive Phase 3 readouts and our colleague Jason Mast to discuss Moderna’s struggles following its Covid-19 vaccine boom.

We also chat about the news this week, including Novo Nordisk’s takeover bid for biotech company Metsera and troubles in the field of genetic medicines.

To learn more on BridgeBio’s positive data, go here; to read the feature on Moderna, go here; for more on Novo’s takeover bid, go here; and for more on Intellia’s decision to pause its gene-editing trials, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.